{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,7]],"date-time":"2026-02-07T02:31:03Z","timestamp":1770431463779,"version":"3.49.0"},"reference-count":34,"publisher":"Cambridge University Press (CUP)","issue":"5","license":[{"start":{"date-parts":[[2020,4,16]],"date-time":"2020-04-16T00:00:00Z","timestamp":1586995200000},"content-version":"unspecified","delay-in-days":5737,"URL":"https:\/\/www.cambridge.org\/core\/terms"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Eur. psychiatr."],"published-print":{"date-parts":[[2004,8]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The objective of this analysis was to evaluate the short- (8 weeks) and long-term (24 weeks) efficacy of three fixed doses of venlafaxine extended release (ER) and placebo on the social adjustment of patients with generalised anxiety disorder (GAD). We analysed data from 544 outpatients who participated in a 24-week, double-blind, multicentre, parallel-group, placebo-controlled study conducted at 55 centres in five countries. All patients meet the DSM-IV criteria for GAD and were randomly assigned to receive venlafaxine ER 37.5, 75, and 150 mg or matched placebo administered orally once daily. Social adjustment was measured using the Social Adjustment Scale-Self Report, which explores social adaptation in the areas of work, social and leisure, extended family, primary relationship (marital), parental, and family unit. At baseline, the GAD patients had a high level of social dysfunction. Venlafaxine ER showed a dose-related improvement in social impairment during short-term treatment and in sustaining this improvement over the long-term. In the most severely socially impaired subgroup, placebo remission rates on the HAM-A were low, and the magnitude of the venlafaxine-placebo difference on the mean HAM-A total score was high, reaching more than 7 points. The benefits of venlafaxine ER treatment of GAD extend beyond that of improvement of anxiety symptoms to a significant improvement in the impairment of functioning that is associated with the illness.<\/jats:p>","DOI":"10.1016\/j.eurpsy.2004.05.010","type":"journal-article","created":{"date-parts":[[2004,8,5]],"date-time":"2004-08-05T04:49:13Z","timestamp":1091681353000},"page":"272-279","source":"Crossref","is-referenced-by-count":11,"title":["Social adjustment in generalised anxiety disorder: a long-term placebo-controlled study of venlafaxine extended release"],"prefix":"10.1017","volume":"19","author":[{"given":"Patrice","family":"Boyer","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vincent","family":"Mah\u00e9","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Hackett","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"56","published-online":{"date-parts":[[2020,4,16]]},"reference":[{"key":"S0924933800016217_ref14","doi-asserted-by":"publisher","DOI":"10.1097\/00004714-199802000-00004"},{"key":"S0924933800016217_ref31","doi-asserted-by":"publisher","DOI":"10.1097\/00005053-197805000-00002"},{"key":"S0924933800016217_ref24","doi-asserted-by":"publisher","DOI":"10.1016\/0022-3999(94)90145-7"},{"key":"S0924933800016217_ref5","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1176\/ajp.143.1.40","article-title":"Generalized anxiety and generalized anxiety disorder: description and reconceptualisation","volume":"143","author":"Barlow","year":"1986","journal-title":"Am J Psychiatry"},{"key":"S0924933800016217_ref12","doi-asserted-by":"publisher","DOI":"10.1017\/S0033291797004807"},{"key":"S0924933800016217_ref15","doi-asserted-by":"publisher","DOI":"10.1007\/BF00583815"},{"key":"S0924933800016217_ref17","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1176\/ajp.144.8.1019","article-title":"A family study of generalized anxiety disorder","volume":"144","author":"Noyes","year":"1987","journal-title":"Am J Psychiatry"},{"key":"S0924933800016217_ref28","first-page":"91","article-title":"Identification of cases of anxiety disorders and affective disorders in the community according to ICD-10 and DSM-III-R by using the Composite International Diagnostic Interview (CIDI)","volume":"2","author":"Wacker","year":"1992","journal-title":"Int J Methods Psychiatr Res"},{"key":"S0924933800016217_ref20","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1001\/archpsyc.1993.01820230054005","article-title":"Antidepressants for the treatment of generalized anxiety disorder. A placebo-controlled comparison of imipramine, trazodone, and diazepam","volume":"50","author":"Rickels","year":"1993","journal-title":"Arch Gen Psychiatry"},{"key":"S0924933800016217_ref11","doi-asserted-by":"publisher","DOI":"10.1016\/S0163-8343(00)00115-8"},{"key":"S0924933800016217_ref6","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v60n0805"},{"key":"S0924933800016217_ref2","volume-title":"DSM-IV: diagnostic and statistical manual of mental disorders.","year":"1994"},{"key":"S0924933800016217_ref22","doi-asserted-by":"publisher","DOI":"10.1097\/00004714-199006001-00017"},{"key":"S0924933800016217_ref29","author":"Weissman","year":"1999","journal-title":"SAS-SR social adjustment scale self-report technical manual"},{"key":"S0924933800016217_ref10","doi-asserted-by":"publisher","DOI":"10.1111\/j.2044-8341.1959.tb00467.x"},{"key":"S0924933800016217_ref1","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.179.1.15"},{"key":"S0924933800016217_ref18","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v62n0508"},{"key":"S0924933800016217_ref3","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1176\/ajp.141.4.572","article-title":"A comparison of panic disorder and generalized anxiety disorder","volume":"141","author":"Anderson","year":"1984","journal-title":"Am J Psychiatry"},{"key":"S0924933800016217_ref4","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1522-7162(1996)4:2<48::AID-DEPR2>3.0.CO;2-B"},{"key":"S0924933800016217_ref7","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0447.1989.tb10263.x"},{"key":"S0924933800016217_ref8","doi-asserted-by":"publisher","DOI":"10.1001\/jama.283.23.3082"},{"key":"S0924933800016217_ref9","article-title":"National Institute of Mental Health (US). Psychopharmacology Research Branch. Early Clinical Drug Evaluation Program. ECDEU assessment manual for psychopharmacology","author":"Guy","year":"1976","journal-title":"Rockville, MD: U.S. Dept. of Health, Education, and Welfare, Public Service, Alcohol, Drug Abuse, and Mental Health Administration, National Institute of Mental Health, Psychopharmacology Research Branch, Division of Extramural Research Programs"},{"key":"S0924933800016217_ref13","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.1994.03950010008002"},{"key":"S0924933800016217_ref19","first-page":"7","article-title":"Antianxiety therapy: potential value of long-term treatment","volume":"48","author":"Rickels","year":"1987","journal-title":"J Clin Psychiatry"},{"key":"S0924933800016217_ref21","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1176\/appi.ajp.157.6.968","article-title":"Efficacy of extended-release venlafaxine in nondepressed outpatients with generalized anxiety disorder","volume":"157","author":"Rickels","year":"2000","journal-title":"Am J Psychiatry"},{"key":"S0924933800016217_ref23","volume-title":"Psychiatric disorders in America: the epidemiologic catchment area study","author":"Robins","year":"1991"},{"key":"S0924933800016217_ref25","doi-asserted-by":"publisher","DOI":"10.1007\/s00213-001-0926-9"},{"key":"S0924933800016217_ref26","volume-title":"Mental illness in general health care: an international study","author":"\u00dcst\u00fcn","year":"1995"},{"key":"S0924933800016217_ref33","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.168.3.308"},{"key":"S0924933800016217_ref34","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0447.1983.tb09716.x"},{"key":"S0924933800016217_ref32","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.1994.03950050015002"},{"key":"S0924933800016217_ref27","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.157.5.723"},{"key":"S0924933800016217_ref16","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1177\/026988110101500404","article-title":"Comparison between noradrenergic and serotonergic medications using the social adjustment scale: is drive enhancement necessary for recovery of social functioning?","volume":"15","author":"Luty","year":"2001","journal-title":"J Psychopharmacol"},{"key":"S0924933800016217_ref30","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.1976.01770090101010"}],"container-title":["European Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924933804001129?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924933804001129?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.cambridge.org\/core\/services\/aop-cambridge-core\/content\/view\/S0924933800016217","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T08:03:08Z","timestamp":1601539388000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cambridge.org\/core\/product\/identifier\/S0924933800016217\/type\/journal_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,8]]},"references-count":34,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2004,8]]}},"alternative-id":["S0924933800016217"],"URL":"https:\/\/doi.org\/10.1016\/j.eurpsy.2004.05.010","relation":{},"ISSN":["0924-9338","1778-3585"],"issn-type":[{"value":"0924-9338","type":"print"},{"value":"1778-3585","type":"electronic"}],"subject":[],"published":{"date-parts":[[2004,8]]}}}